Establishment of Multiparametric Prediction Models for Moderate to Severe Thyroid Associated Ophthalmopathy

What this Trial Is About

Thyroid-associated ophthalmopathy (TAO) is an autoimmune disease linked to thyroid problems, commonly causing orbital disease in adults and often associated with Graves disease. The symptoms of TAO vary widely, and in severe cases, it can seriously harm vision and daily life, potentially causing corneal damage and blindness. Researchers are aiming to find new diagnostic markers or imaging techniques and to create a detailed prediction model for moderate to severe TAO to improve diagnosis and management. This observational study will monitor participants diagnosed with moderate to severe TAO according to established criteria. The study focuses on collecting clinical information and imaging data to develop and validate a multiparametric prediction model. There are no drug or treatment interventions; instead, participants will undergo assessments and imaging relevant to their condition as part of the study process. Participants will be evaluated at various times, including assessments of overall response at 1, 24, 52, and 104 weeks after the end of treatment. Researchers will also monitor changes in blood markers related to thyroid function and lipid levels over 104 weeks. Safety will be assessed by recording any non-serious adverse events shortly after treatment. The total participation duration covers over two years, with regular follow-ups and data collection to understand TAO progression and treatment outcomes.

Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy